secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ginkgo Bioworks Holdings, Inc. (DNA)
CIK:        0001830214
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001628280-26-032093
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ginkgo Bioworks Q1 revenue $19M (-49% YoY); narrows net loss; cash burn guidance reaffirmed
--------------------------------------------------------------------------------

- Revenue $19M, down 49% YoY; prior year included $7M non-cash deferred revenue release; adjusted EBITDA -$42M.
- GAAP net loss from continuing ops -$76M (vs -$83M prior year); operating cash burn trajectory reaffirmed.
- Completed Biosecurity divestiture on April 3, 2026; results presented as discontinued ops.
- Cash, cash equivalents and marketable securities $373M as of March 31, 2026.
- Reaffirms FY 2026 total cash burn guidance of $(150)-$(125) million.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1830214/000162828026032093/0001628280-26-032093-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1830214/000162828026032093/dna-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-032093

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer